2019年ACR/EULAR IgG4相关性疾病分类标准
ACR/EULAR组织86名多学科医师,基于1879例受试者(1086例病例,793例模拟者)的推导与验证队列,采用共识、文献、决策分析制定并验证IgG4-RD分类标准。标准为三步法:11个器官中至少1个受累、32项排除标准、8个加权纳入域,阈值20分时两个验证队列的 specificity 分别为99.2%和97.8%,sensitivity 分别为85.5%和82.0%。
要点
- 三步分类:器官受累+排除标准+加权纳入域,阈值20分。
- 验证队列特异性99.2%/97.8%,敏感性85.5%/82.0%。
- 分类标准适用于临床、流行病学和基础研究。
核心结论
- ACR/EULAR IgG4-RD分类标准已在大规模队列中开发并验证,具有优良的检测性能。
研究设计与样本
- 国际多学科小组由ACR和EULAR组建,共86名医师参与。
- 使用共识练习、现有文献、1879例受试者(1086例病例,793例模拟者)的推导与验证队列及多标准决策分析。
- 包含两个独立验证队列。
主要发现
- 开发了三步分类流程:首先证明至少1个可能的11个器官受累且符合IgG4-RD;其次应用32项排除标准,存在任一即排除;最后应用8个加权纳入标准域。
- 第一验证队列阈值20分时特异性99.2%(95%CI 97.2-99.8%),敏感性85.5%(95%CI 81.9-88.5%)。
- 第二验证队列特异性97.8%(95%CI 93.7-99.2%),敏感性82.0%(95%CI 77.0-86.1%)。
- 标准在广泛阈值范围内具有稳健的检测特性。
关键数值与推荐
- 分类需满足至少1个11个可能器官的IgG4-RD一致性受累。
- 32项临床、血清学、影像学和病理学排除标准中任一存在即排除分类。
- 8个加权纳入标准域涵盖临床、血清学、影像学和病理学。
- 第一验证队列阈值20分:特异性99.2%(95%CI 97.2-99.8%),敏感性85.5%(95%CI 81.9-88.5%)。
- 第二验证队列阈值20分:特异性97.8%(95%CI 93.7-99.2%),敏感性82.0%(95%CI 77.0-86.1%)。
临床怎么用
- 临床研究中采用三步法对疑似IgG4-RD患者进行分类,阈值20分。
- 分类前需排除32项排除标准中的任一情况。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: IgG4-related disease (IgG4-RD) can cause fibroinflammatory lesions in nearly any organ. Correlation among clinical, serologic, radiologic, and pathologic data is required for diagnosis. This work was undertaken to develop and validate an international set of classification criteria for IgG4-RD. METHODS: An international multispecialty group of 86 physicians was assembled by the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR). Investigators used consensus exercises, existing literature, derivation and validation cohorts of 1,879 subjects (1,086 cases, 793 mimickers), and multicriterion decision analysis to identify, weight, and test potential classification criteria. Two independent validation cohorts were included. RESULTS: A 3-step classification process was developed. First, it must be demonstrated that a potential IgG4-RD case has involvement of at least 1 of 11 possible organs in a manner consistent with IgG4-RD. Second, exclusion criteria consisting of a total of 32 clinical, serologic, radiologic, and pathologic items must be applied; the presence of any of these criteria eliminates the patient from IgG4-RD classification. Third, 8 weighted inclusion criteria domains, addressing clinical findings, serologic results, radiology assessments, and pathology interpretations, are applied. In the first validation cohort, a threshold of 20 points had a specificity of 99.2% (95% confidence interval [95% CI] 97.2-99.8%) and a sensitivity of 85.5% (95% CI 81.9-88.5%). In the second, the specificity was 97.8% (95% CI 93.7-99.2%) and the sensitivity was 82.0% (95% CI 77.0-86.1%). The criteria were shown to have robust test characteristics over a wide range of thresholds. CONCLUSION: ACR/EULAR classification criteria for IgG4-RD have been developed and validated in a large cohort of patients. These criteria demonstrate excellent test performance and should contribute substantially to future clinical, epidemiologic, and basic science investigations.
引用
- Wallace ZS, Naden RP, Chari S, et al. The 2019 American College of Rheumatology/European League Against Rheumatism Classification Criteria for IgG4-Related Disease. Arthritis Rheumatol. 2019. PMID: 31793250. doi:10.1002/art.41120
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。